Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA)has given orphan drug status to Soligenix's ricin intoxication preventive, RiVax.
Subscribe to our email newsletter
Soligenix has completed a Phase 1A clinical trial of RiVax which showed that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure.
Further, the company is continuing Phase 1B trial of RiVax.
Soligenix president and CEO Christopher Schaber said the FDA’s decision to grant RiVax orphan drug designation for the prevention of ricin intoxication marks another important step forward in their biodefense pipeline.
"Marketing exclusivity through orphan drug designation adds significantly to the existing patent estate surrounding RiVax," Schaber said.